XML 31 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 13 – Segment Reporting

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (CODM) in deciding how to allocate resources and assess performance. The Company's Chief Executive Officer and Chief Financial Officer, as a group, represents the entity's chief operating decision makers. The Company’s CODM views the Company’s operations and manages its business as a single operating segment focused on diagnostic testing in the clinical setting and providing services to biopharmaceutical companies (see Note 9 – Revenue and Accounts Receivable Credit Concentration). The CODM views the Company's operations as a single operating segment as each revenue stream utilizes the same equipment and resources. In addition, discrete financial information is not available for each revenue stream other than gross margin. The accounting policies of the segment are the same as those described in Note 2 – Summary of Significant Accounting Policies.

Substantially all of the Company’s revenue and all long-lived assets were derived or are located in the United States for the three and nine months ended September 30, 2025 and 2024. The measure of segment assets is reported on the balance sheet as total assets.

As a single operating segment, the CODM assesses how to allocate resources and measures the Company's performance based on net income or loss that is reported on the statement of operations as net loss. The CODM uses net income or loss to evaluate the return generated from segment assets in deciding whether to reinvest into the segment or into other parts of the entity, such as acquisitions. Net income or loss is used to monitor budget versus actual results, which are used in assessing performance of the segment and in establishing management's compensation.

The CODM regularly reviews the following significant expenses and other segment items. A summary of the significant expenses and other segment items reported in the Company’s statements of operations as of the dates indicated is as follows (in thousands):

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2025

 

 

2024

 

2025

 

 

2024

 

Revenues

 

$

21,768

 

 

$

18,151

 

$

59,744

 

 

$

50,894

 

Less:

 

 

 

 

 

 

 

 

 

 

 

Direct costs and expenses (less employee related expenses and depreciation and amortization)

 

 

3,061

 

 

 

3,207

 

 

8,634

 

 

 

8,296

 

Employee related expenses (less share-based compensation expenses)

 

 

16,933

 

 

 

14,109

 

 

48,703

 

 

 

41,014

 

Contracted services expenses

 

 

1,511

 

 

 

1,771

 

 

5,691

 

 

 

4,811

 

Sales and marketing education and event expenses

 

 

1,748

 

 

 

1,619

 

 

5,601

 

 

 

6,057

 

Occupancy and equipment service expenses

 

 

1,129

 

 

 

975

 

 

3,079

 

 

 

3,071

 

Clinical trials and associated costs

 

 

284

 

 

 

268

 

 

1,287

 

 

 

912

 

Depreciation and amortization expense

 

 

1,406

 

 

 

1,493

 

 

4,283

 

 

 

4,324

 

Share-based compensation expenses

 

 

1,053

 

 

 

1,515

 

 

3,064

 

 

 

5,373

 

Interest expense

 

 

2,074

 

 

 

2,041

 

 

5,657

 

 

 

6,506

 

Change in fair value of warrant liability, net

 

 

—

 

 

 

—

 

 

280

 

 

 

—

 

Other segment items (1)

 

 

1,285

 

 

 

1,411

 

 

4,750

 

 

 

5,210

 

Net loss

 

$

(8,716

)

 

$

(10,258

)

$

(31,285

)

 

$

(34,680

)
(1)
Other segment items in segment net loss primarily include software and IT related expenses, administrative and professional development expenses, risk management and insurance expenses, other non-cash expenses, and allocated overhead expenses.